What Does the Test Show?
Quantifying both the quantity and quality of antibodies against 12 variants of COVID will classify the patient into 3 distinct classifications:
- Hyper-immune
- Hypo-immune / Immune-compromised
- Unremarkable
Finding your unique spectrum can lead to improved treatment with one of our partner Clinics.
Find out more about the science in the webinar below:

Trusted by Clinicians
“We need to investigate the causes and treatment of viral persistance. We have been using the Attomarker test to identify our patients with persistent COVID activity”
Dr Ben Sinclair
Long COVID Specialist
featured in The Sunday Times
Trusted by Patients
“Attomarker’s blood test has been a game changer, enabling me to understand and manage my Long COVID. There’s nothing else like it available throguh NHS Long COVID clinics”
Patient Testimonial
Contemplating Antibody Intervention?
Monoclonal antibody (mAb) therapies like Sipavibart and Pemgarda are emerging as a potential treatment for Long COVID, targeting the lingering immune dysregulation that some patients experience after acute infection. These lab-engineered antibodies mimic the body’s natural immune response by binding to specific viral proteins or inflammatory markers.
What’s New & Exciting?
Crowdfunding the Long Covid Journey
Why Attomarker chose a public funding route for work in Long Covid When someone tells you Long Covid is “too short ...
Lyme Disease and Long Lyme: The Patient Struggle and How Attomarker Hopes to Change That
In our previous article, we set out the numbers: over 700,000 new Lyme disease cases globally each year, a Long Lyme ...
The Scale of Lyme Disease and Long Lyme: A Global Burden in Numbers
Lyme disease is the most common vector-borne disease in the Northern Hemisphere, yet its true scale remains remarkabl...
EpitogenX and Attomarker Sign Strategic Co-Development Agreement
Cheltenham and Exeter, United Kingdom, 17th February 2026 (Updated) EpitogenX and Attomarker Sign Strategic Co-Develo...
Immune endotypes and why immune profiling matters in Long Covid
Long Covid is still commonly approached as though it were a single condition. Patients are grouped under one label, t...
What an Acceleration Round means for Attomarker at this stage
As Attomarker enters its next phase of development, we have announced that the company is undertaking an Acceleration...
Attomarker launches Acceleration Round
February 6, 2026 Attomarker launches Acceleration Round to further progress commercial, regulatory and business devel...
When 74 Million Patients Is Considered “Too Short Term”
Professor Andrew Shaw, Founder & Chief Scientist, Attomarker Ltd The comment that stopped the conversation I have...
Confronting Long COVID: The Persistent Virus Hypothesis
The Immune Response to SARS-CoV-2 and Long COVID Long COVID is currently reported to affect as many as one in five...
Attomarker To Lead New Medical Intervention to Explore Monoclonal Antibody Treatment for Long COVID
EXETER, UK – 4 April 2025 – Attomarker, a leader in rapid diagnostic technology, today announced its plans for a new...
International Long COVID Awareness Day 2025
International Long COVID Awareness Day 2025 Five Years On, Long COVID Patients Are Still Being Left Behind On...
Treating Long Covid: The Persistent Virus Hypothesis
A Novel Diagnosis and Treatment TO BOOK YOUR ANTIBODY IMMUNITY SPECTRUM TEST: Visit our clinics Elimination of...
















